Donald L. Price

Last updated

Donald L. Price (1935-2023) [1] was an American neuropathologist and professor at the Johns Hopkins School of Medicine. His research aimed to understand the molecular basis of neurodegenerative diseases, particularly Alzheimer's disease. Price received a number of awards for his work and served as the President of both the American Association of Neuropathologists and the Society for Neuroscience. [2]

Contents

Early life

Price was born in Stamford, Connecticut. He attended Wesleyan University, where he received a Bachelor of Arts in English Literature. In 1961, he received his medical degree from Albany Medical College of Union University. Following graduation, Dr. Price was a Medical Intern and Resident at the New England Medical Center, Boston, MA ( 1961–1963), and he completed a Neurology Residency at the Massachusetts General Hospital, Boston, MA (1963-1968). He was a Staff Neurologist at the National Naval Medical Center in Bethesda, Maryland (1966-1968). He returned to Boston as a Senior Fellow in Neuropathology at Mass General (1968-1969) and as a Research Fellow in Cell/Molecular Biology (with Keith Porter)(1969-1970) at Harvard University. [1]

Career

Price's first faculty appointment was as an assistant professor in the Departments of Neurology and Pathology at Harvard Medical School in 1970. In 1971, he was recruited to the Johns Hopkins School of Medicine, becoming the Founding Director of the Division of Neuropathology. At Hopkins, Price was a professor of pathology, Neurology, and Neuroscience.

Price served as President of the American Association of Neuropathologists from 1989 to 1990. [3] From 2000 to 2001, he served as President of the Society for Neuroscience. Price was a member of The Institute of Medicine (National Academy of Sciences)(1998). [4]

Over the course of his career, Price trained hundreds of medical and graduate students, house officers and postdoctoral fellows. His trainees include many prominent basic scientists and clinicians at a variety of medical schools, universities, and government institutions. [5] During the “Decade of the Brain“ (1990-2000), Price was ranked among the top ten neuroscientists as authors of high-impact papers in neuroscience by Science Watch (12 102 2001).

Research

Price first focused on the biology of motor neurons, but later in his career, he became interested in brain mechanisms underlying neurodegenerative diseases, particularly [Alzheimer's disease]”. [6] He often used animal models in order to “allow a more direct insight into pathogenesis”, in parallel with comparative analyses of disease in humans. His work with transgenic mice sought to experimentally test new treatment mechanisms before they reached human subjects. [7] These studies identified specific genes that are often risk factors, particularly genes related to the generation and aggregation of Amyloid beta, a key component of Abeta plaques in the brain.

Defects in the Brain due to Alzheimer's disease TANGLES HIGH.jpg
Defects in the Brain due to Alzheimer's disease

In 1985, Price became Principal Investigator of the Alzheimer's Disease Research Center at Johns Hopkins University, one of the first federally funded Alzheimer's Disease Research Centers in the United States.

Awards and honors

YearAward/Honor
1989Metropolitan Life Foundation Award [8]
1990President of the American Association of Neuropathologists
1992Potamkin Prize for Alzheimer's Disease Research
1994Leadership in Alzheimer's Disease (LEAD) Award (National Institute of Aging)
2000-2001President of the Society for Neuroscience
2001Wartenberg Award [9]
2012The Award for Meritorious Contributions to Neuropathology [6]
2015AAIC Lifetime Achievement Awards in Alzheimer's Disease [10]
1986 20002 Javits Neuroscience Investigator Merit Awards (National Institute of Neurological Disorders and Stroke) [2]

Publications

Below are some of Price's highly cited publications: [6]

Related Research Articles

<span class="mw-page-title-main">Alois Alzheimer</span> German psychiatrist and neuropathologist (1864–1915)

Alois Alzheimer was a German psychiatrist and neuropathologist and a colleague of Emil Kraepelin. Alzheimer is credited with identifying the first published case of "presenile dementia", which Kraepelin would later identify as Alzheimer's disease.

<span class="mw-page-title-main">Neuropathology</span> Study of disease of nervous system tissue

Neuropathology is the study of disease of nervous system tissue, usually in the form of either small surgical biopsies or whole-body autopsies. Neuropathologists usually work in a department of anatomic pathology, but work closely with the clinical disciplines of neurology, and neurosurgery, which often depend on neuropathology for a diagnosis. Neuropathology also relates to forensic pathology because brain disease or brain injury can be related to cause of death. Neuropathology should not be confused with neuropathy, which refers to disorders of the nerves themselves rather than the tissues. In neuropathology, the branches of the specializations of nervous system as well as the tissues come together into one field of study.

<span class="mw-page-title-main">Amyloid plaques</span> Extracellular deposits of the amyloid beta protein

Amyloid plaques are extracellular deposits of the amyloid beta (Aβ) protein mainly in the grey matter of the brain. Degenerative neuronal elements and an abundance of microglia and astrocytes can be associated with amyloid plaques. Some plaques occur in the brain as a result of aging, but large numbers of plaques and neurofibrillary tangles are characteristic features of Alzheimer's disease. The plaques are highly variable in shape and size; in tissue sections immunostained for Aβ, they comprise a log-normal size distribution curve, with an average plaque area of 400-450 square micrometers (μm2). The smallest plaques, which often consist of diffuse deposits of Aβ, are particularly numerous. Plaques form when Aβ misfolds and aggregates into oligomers and longer polymers, the latter of which are characteristic of amyloid.

<span class="mw-page-title-main">Neurofibrillary tangle</span> Aggregates of tau protein known as a biomarker of Alzheimers disease

Neurofibrillary tangles (NFTs) are intracellular aggregates of hyperphosphorylated tau protein that are most commonly known as a primary biomarker of Alzheimer's disease. Their presence is also found in numerous other diseases known as tauopathies. Little is known about their exact relationship to the different pathologies.

Neuropsychiatry is a branch of medicine that deals with psychiatry as it relates to neurology, in an effort to understand and attribute behavior to the interaction of neurobiology and social psychology factors. Within neuropsychiatry, the mind is considered "as an emergent property of the brain", whereas other behavioral and neurological specialties might consider the two as separate entities. Those disciplines are typically practiced separately.

The biochemistry of Alzheimer's disease, the most common cause of dementia, is not yet very well understood. Alzheimer's disease (AD) has been identified as a proteopathy: a protein misfolding disease due to the accumulation of abnormally folded amyloid beta (Aβ) protein in the brain. Amyloid beta is a short peptide that is an abnormal proteolytic byproduct of the transmembrane protein amyloid-beta precursor protein (APP), whose function is unclear but thought to be involved in neuronal development. The presenilins are components of proteolytic complex involved in APP processing and degradation.

<span class="mw-page-title-main">Proteinopathy</span> Medical condition

In medicine, proteinopathy, or proteopathy, protein conformational disorder, or protein misfolding disease, is a class of diseases in which certain proteins become structurally abnormal, and thereby disrupt the function of cells, tissues and organs of the body. Often the proteins fail to fold into their normal configuration; in this misfolded state, the proteins can become toxic in some way or they can lose their normal function. The proteinopathies include such diseases as Creutzfeldt–Jakob disease and other prion diseases, Alzheimer's disease, Parkinson's disease, amyloidosis, multiple system atrophy, and a wide range of other disorders. The term proteopathy was first proposed in 2000 by Lary Walker and Harry LeVine.

The Nun Study of Aging and Alzheimer's Disease is a continuing longitudinal study, begun in 1986, to examine the onset of Alzheimer's disease. David Snowdon, an Epidemiologist and the founding Nun Study investigator, started the Nun Study at the University of Minnesota, later transferring the study to the University of Kentucky in 1990. In 2008, with Snowdon's retirement, the study returned to the University of Minnesota. The Nun Study was very briefly moved from the University of Minnesota to Northwestern University in 2021 under the directorship of Dr. Margaret Flanagan. The Nun Study is currently housed at the University of Texas Health San Antonio in the Bigg's Institute for Alzheimer's and Neurodegenerative diseases under the continued directorship of Neuropathologist, Dr. Margaret Flanagan.

John Quinn Trojanowski was an American academic research neuroscientist specializing in neurodegeneration. He and his partner, Virginia Man-Yee Lee, MBA, Ph.D., are noted for identifying the roles of three proteins in neurodegenerative diseases: tau in Alzheimer's disease, alpha-synuclein in Parkinson's disease, and TDP-43 in Amyotrophic Lateral Sclerosis (ALS) and frontotemporal degeneration.

<span class="mw-page-title-main">Alzheimer's disease</span> Progressive neurodegenerative disease

Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the average life expectancy following diagnosis is three to twelve years.

<span class="mw-page-title-main">Anne B. Young</span> American neuroscientist

Anne Buckingham Young is an American physician and neuroscientist who has made major contributions to the study of neurodegenerative diseases, with a focus on movement disorders like Huntington's disease and Parkinson's disease. Young completed her undergraduate studies at Vassar College and earned a dual MD/PhD from Johns Hopkins Medical School. She has held faculty positions at University of Michigan and Harvard University. She became the first female chief of service at Massachusetts General Hospital when she was appointed Chief of Neurology in 1991. She retired from this role and from clinical service in 2012. She is a member of many academic societies and has won numerous awards. Young is also the only person to have been president of both the international Society for Neuroscience and the American Neurological Association.

<span class="mw-page-title-main">Tara Spires-Jones</span> Professor of Neurodegeneration

Tara Spires-Jones is professor of neurodegeneration and deputy director of the Centre for Discovery Brain Sciences at the University of Edinburgh. She is also a group leader in the UK Dementia Research Institute.

<span class="mw-page-title-main">Virginia Man-Yee Lee</span> American neuroscientist and biochemist

Virginia Man-Yee Lee is a Chinese-born American biochemist and neuroscientist who specializes in the research of Alzheimer's disease. She is the current John H. Ware 3rd Endowed Professor in Alzheimer's Research at the Department of Pathology and Laboratory Medicine, and the director of the Center for Neurodegenerative Disease Research and co-director of the Marian S. Ware Alzheimer Drug Discovery Program at the Perelman School of Medicine, University of Pennsylvania. She received the 2020 Breakthrough Prize in Life Sciences.

Colin Louis MastersMD is an Australian neuropathologist who researches Alzheimer's disease and other neurodegenerative disorders. He is laureate professor of pathology at the University of Melbourne.

Mathias Jucker is a Swiss neuroscientist, Professor, and a Director at the Hertie Institute for Clinical Brain Research of the University of Tübingen. He is also a group leader at the German Center for Neurodegenerative Diseases in Tübingen. Jucker is known for his research on the basic biologic mechanisms underlying brain aging and Alzheimer's disease.

<span class="mw-page-title-main">Eva Braak</span> German anatomist

Eva Braak (1939-2000) was a German anatomist, mostly known for the Braak and Braak Alzheimer disease stages. She was professor at the Institute of Clinical Neuroanatomy, Johann Wolfgang Goethe-University, Frankfurt am Main.

Lary Walker is an American neuroscientist and researcher at Emory University in Atlanta, Georgia. He is Associate Director of the Goizueta Alzheimer's Disease Research Center at Emory, and he is known for his research on the role of abnormal proteins in the causation of Alzheimer's disease.

Mel B. Feany is an American neuropathologist and geneticist at Brigham and Women's Hospital who researches neurodegenerative disease. She is a co-editor of the Annual Review of Pathology: Mechanisms of Disease.

Gerard David Schellenberg is an academic neuropathologist who specializes in the research of Alzheimer's disease. He is the director of Penn Neurodegeneration Genomics Center as well as a professor of Pathology and Laboratory Medicine at the University of Pennsylvania. He is a leading contributor to Alzheimer's disease research.

Kevin A. Roth is an American neuropathologist and former Chair of Pathology at Columbia University and the University of Alabama at Birmingham (UAB). He was the President of the American Society for Investigative Pathology from 2014-2015, and performed research for over three decades on apoptotic cell death in neural development, neurodegenerative disease, and tumors of the nervous system.

References

  1. 1 2 "Donald Price Obituary". Legacy.com .
  2. 1 2 "The Donald L. Price Research Fund" (PDF). Johns Hopkins Medicine. May 18, 2008.
  3. "Past Presidents and Officers". www.neuropath.org. Retrieved 2020-03-30.
  4. "SfN Presidents". www.sfn.org. Retrieved 2020-03-30.
  5. "Neurotree - Donald L. Price Family Tree".
  6. 1 2 3 Troncoso, Juan (2012-11-01). "Meritorious Contributions to Neuropathology". Journal of Neuropathology & Experimental Neurology. 71 (11): 1030–1031. doi: 10.1097/NEN.0b013e318273643e . ISSN   0022-3069.
  7. Price, D. L.; Tanzi, R. E.; Borchelt, D. R.; Sisodia, S. S. (1998). "Alzheimer's disease: genetic studies and transgenic models". Annual Review of Genetics. 32: 461–493. doi:10.1146/annurev.genet.32.1.461. ISSN   0066-4197. PMID   9928488.
  8. "Winners | MetLife Foundation Awards in Medical Research". mlfawards.afar.org. Archived from the original on 2012-01-23. Retrieved 2020-03-30.
  9. "Plenary History". www.aan.com. Retrieved 2020-03-30.
  10. "AAIC 2019 - Awards". AAIC. 2016-03-18. Retrieved 2020-03-30.